FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.

Treating Life-Threatening Bleedings

Ulla Hedner
    Product form
      FORMAT: Paperback / softback
      YOU COULD EARN 0 FUTURE RETAIL DISCOUNTS.

      This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist

      ESTIMATED DELIVERY: Possibly out of print
      BUY NOW PAY LATER
      From R 0.00 per month!
      3x monthly payments of R 0.00 with
      4x fortnightly payments of R 0.00 with

      This product is either out of print or out of stock. Add it to your wishlist and we will automatically let you know if it comes back into stock. Add to Wishlist

      Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.
      Format: CONTRIBUTORS: Ulla Hedner EAN: 9780128124390 COUNTRY: United States PAGES: WEIGHT: 360 g HEIGHT: 229 cm
      PUBLISHED BY: Elsevier Science Publishing Co Inc DATE PUBLISHED: 2017-07-06 CITY: GENRE: MEDICAL / Hematology WIDTH: 152 cm SPINE:

      Book Themes:

      Haematology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark. Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983 . Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.
      Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work. The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.
      Format: CONTRIBUTORS: Ulla Hedner EAN: 9780128124390 COUNTRY: United States PAGES: WEIGHT: 360 g HEIGHT: 229 cm
      PUBLISHED BY: Elsevier Science Publishing Co Inc DATE PUBLISHED: 2017-07-06 CITY: GENRE: MEDICAL / Hematology WIDTH: 152 cm SPINE:

      Book Themes:

      Haematology

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      Dr. Hedner has been active in the field of Thrombosis and Haemostasis for more than 40 years and initiated the idea to use FVIIa as a hemostatic drug when working as a clinician at the University Hospital of Malmö, Lund University, Sweden, in the 1970s. Later, she led the development of recombinant FVIIa when being part of the Department of Research & Development at the Danish pharmaceutical company Novo Nordisk A/S, Bagsværd, Denmark. Dr. Hedner was a physician at the Department of Bleeding Disorders including a Haemophilia Comprehensive Clinic, Malmö University Hospital, University of Lund, Sweden from 1972-1983 . Her research and teaching experience was at the Medical Faculty of Lund University, Sweden and Professor in Clinical Coagulation Research at the University of Gothenburg and at the University of Lund.

      Recently viewed products

      Login

      Forgot your password?

      Don't have an account yet?
      Create account